

May 2021

**METAL TRADES BRANCH WELFARE FUND
SUMMARY OF MATERIAL MODIFICATION**

IMPORTANT BENEFIT ANNOUNCEMENT

*This summary of material modification ("SMM") describes important changes to the Metal Trades Branch Welfare Fund and supplements the Summary Plan Description (SPD). **The effective date of this notice is May 6, 2021.** You should read the SMM very carefully and retain this document with your copy of the SPD for future reference.*

This change will help the Welfare Fund to continue to provide you and your families with the comprehensive coverage that you need that is affordable to you and the Fund.

Gene Therapy Exclusion

Gene therapy typically involves replacing a gene that causes a medical problem with one that does not, adding genes to help fight or treat disease, or inactivating genes that cause medical problems.

Effective May 6, 2021 the Welfare Fund will exclude coverage under the hospital, medical and prescription drug coverage for or related to gene therapy, whether those therapies have received approval from the U.S. Food and Drug Administration or

are considered experimental or investigational. Examples of gene therapy include, but are not limited to, Chimeric Antigen Receptor T-Cell (CAR-T) Therapies such as Kymriah and Yescarta as well as Luxturna and Zolgensma.

This exclusion will apply to any and all new gene therapies that become available in the future.

~ ~ ~ ~ ~

Should you have any questions regarding this benefit announcement or about any aspect of your employee benefit programs please contact the Fund Office at 212.465.8888.

**THE TRUSTEES OF THE
METAL TRADES BRANCH WELFARE FUND**

Michael Mulvaney (Co-Chairman)
Patrick Dolan
Daniel Mulligan
Clifford Ryder

Jerome Morreale (Co-Chairman)
Jennifer Dehardt
Marc Newman
Anthony Saporito